Y101D

Y101D is a recombinant humanized bispecific antibody that simultaneously targets and inhibits both programmed death-ligand 1 (PD-L1) and transforming growth factor beta (TGF-β). By blocking these two immunosuppressive pathways, Y101D aims to enhance anti-tumor immune responses in the tumor microenvironment. Preclinical studies have shown that dual blockade of PD-L1 and TGF-β with agents like YM101 (a related molecule) can promote T cell infiltration into tumors, normalize the immune microenvironment, and produce superior anti-tumor effects compared to monotherapies targeting either pathway alone. The drug is being developed primarily for the treatment of advanced solid tumors including hepatocellular carcinoma and pancreatic cancer. It is under clinical investigation in China by Wuhan YZY Biopharma[1][3][4][5][8].

Other names

anti-PD-L1/TGF-beta bispecific antibody Y101D